Istradefylline is an adenosine receptor antagonist that is used as adjunctive therapy to levodopa/carbidopa in patients with Parkinson disease experiencing difficulty with “off” episodes when motor symptoms breakthrough on treatment. Istradefylline has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent liver injury with jaundice. It is grouped under the following drug class(es): Dopamine agents and Neurotransmitter agents. Its therapeutic use is listed as antiparkinsonian agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include KW-6002, nouriast, Nourianz and KW 6002. Its PubChem CID is 5311037.
Istradefylline
| CAS No | 155270-99-8 |
|---|---|
| Molecular Formula | C20H24N4O4 |
| Molecular Weight | 384.4 g/mol |
| Synonyms | 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Istradefylline is an adenosine receptor antagonist that is used as adjunctive therapy to levodopa/carbidopa in patients with Parkinson disease experiencing difficulty with “off” episodes when motor symptoms breakthrough on treatment.
The listed CAS number is 155270-99-8.
The listed molecular formula is C20H24N4O4.
The listed molecular weight is 384.4 g/mol.
8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione.
The source lists KW-6002, nouriast, Nourianz and KW 6002.